Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study von Subbiah, Vivek, Hu, Mimi I, Wirth, Lori J, Schuler, Martin, Mansfield, Aaron S, Curigliano, Giuseppe, Brose, Marcia S, Zhu, Viola W, Leboulleux, Sophie, Bowles, Daniel W, Baik, Christina S, Adkins, Douglas, Keam, Bhumsuk, Matos, Ignacio, Garralda, Elena, Gainor, Justin F, Lopes, Gilberto, Lin, Chia-Chi, Godbert, Yann, Sarker, Debashis, Miller, Stephen G, Clifford, Corinne, Zhang, Hui, Turner, Christopher D, Taylor, Matthew H

Volltext

Hypercalcemia and cancer: Differential diagnosis and treatment von Zagzag, Jonathan, Hu, Mimi I., Fisher, Sarah B., Perrier, Nancy D.

Volltext

Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline von El-Hajj Fuleihan, Ghada, Clines, Gregory A, Hu, Mimi I, Marcocci, Claudio, Murad, M Hassan, Piggott, Thomas, Van Poznak, Catherine, Wu, Joy Y, Drake, Matthew T

Volltext

Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns von Nguyen, Ha, Shah, Komal, Waguespack, Steven G, Hu, Mimi I, Habra, Mouhammed Amir, Cabanillas, Maria E, Busaidy, Naifa L, Bassett, Roland, Zhou, Shouhao, Iyer, Priyanka C, Simmons, Garrett, Kaya, Diana, Pitteloud, Marie, Subudhi, Sumit K, Diab, Adi, Dadu, Ramona

Volltext

Adverse events associated with bone-directed therapies in patients with cancer von Jara, Mark A., Varghese, Jeena, Hu, Mimi I.

Volltext

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions von Hamidi, Sarah, Hu, Mimi I.

Volltext

Precision Targeted Therapy with BLU-667 for RET -Driven Cancers von Subbiah, Vivek, Gainor, Justin F, Rahal, Rami, Brubaker, Jason D, Kim, Joseph L, Maynard, Michelle, Hu, Wei, Cao, Qiongfang, Sheets, Michael P, Wilson, Douglas, Wilson, Kevin J, DiPietro, Lucian, Fleming, Paul, Palmer, Michael, Hu, Mimi I, Wirth, Lori, Brose, Marcia S, Ou, Sai-Hong Ignatius, Taylor, Matthew, Garralda, Elena, Miller, Stephen, Wolf, Beni, Lengauer, Christoph, Guzi, Timothy, Evans, Erica K

Volltext

Letter to the Editor: ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma von Alsharif, Omar, Panella, Timothy, Nodit, Laurentia, Hu, Mimi I

Volltext

Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules von Hu, Mimi I, Waguespack, Steven G, Dosiou, Chrysoula, Ladenson, Paul W, Livhits, Masha J, Wirth, Lori J, Sadow, Peter M, Krane, Jeffrey F, Stack, Brendan C, Zafereo, Mark E, Ali, Syed Z, Weitzman, Steven P, Hao, Yangyang, Babiarz, Joshua E, Kennedy, Giulia C, Kloos, Richard T

Volltext

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors von Iyer, Priyanka C., Cabanillas, Maria E., Waguespack, Steven G., Hu, Mimi I., Thosani, Sonali, Lavis, Victor R., Busaidy, Naifa L., Subudhi, Sumit K., Diab, Adi, Dadu, Ramona

Volltext

Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance von Hamidi, Sarah, Hofmann, Marie-Claude, Iyer, Priyanka C, Cabanillas, Maria E, Hu, Mimi I, Busaidy, Naifa L, Dadu, Ramona

Volltext

Reply to Letter to the Editor regarding “Decreased utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer” von Maniakas, Anastasios, Hu, Mimi I., Gunn, G. Brandon, Zafereo, Mark

Volltext

RET kinase inhibitors for RET-altered thyroid cancers von Vodopivec, Danica M., Hu, Mimi I.

Volltext

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study von Subbiah, Vivek, Hu, Mimi I, Mansfield, Aaron S, Taylor, Matthew H, Schuler, Martin, Zhu, Viola W, Hadoux, Julien, Curigliano, Giuseppe, Wirth, Lori, Gainor, Justin F, Alonso, Guzman, Adkins, Douglas, Godbert, Yann, Ahn, Myung-Ju, Cassier, Philippe A, Cho, Byoung Chul, Lin, Chia-Chi, Zalutskaya, Alena, Barata, Teresa, Trask, Peter, Scalori, Astrid, Bordogna, Walter, Heinzmann, Sebastian, Brose, Marcia S

Volltext

Genetic profiling as a clinical tool in advanced parathyroid carcinoma von Kutahyalioglu, Merve, Nguyen, Ha T., Kwatampora, Lily, Clarke, Callisia, Silva, Angelica, Ibrahim, Eiman, Waguespack, Steven G., Cabanillas, Maria E., Jimenez, Camilo, Hu, Mimi I., Sherman, Steven I., Kopetz, Scott, Broaddus, Russell, Dadu, Ramona, Wanland, Kacey, Williams, Michelle, Zafereo, Mark, Perrier, Nancy, Busaidy, Naifa L.

Volltext

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET -mutant medullary thyroid cancer von Wirth, Lori J, Brose, Marcia S, Elisei, Rossella, Capdevila, Jaume, Hoff, Ana O, Hu, Mimi I, Tahara, Makoto, Robinson, Bruce, Gao, Ming, Xia, Meng, Maeda, Patricia, Sherman, Eric

Volltext

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer von Hadoux, Julien, Elisei, Rossella, Brose, Marcia S., Hoff, Ana O., Robinson, Bruce G., Gao, Ming, Jarzab, Barbara, Isaev, Pavel, Kopeckova, Katerina, Wadsley, Jonathan, Führer, Dagmar, Keam, Bhumsuk, Bardet, Stéphane, Sherman, Eric J., Tahara, Makoto, Hu, Mimi I., Singh, Ravinder, Lin, Yan, Soldatenkova, Victoria, Wright, Jennifer, Lin, Boris, Maeda, Patricia, Capdevila, Jaume, Wirth, Lori J.

Volltext

Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat—and With Which Drug—Those Are the Questions von Cabanillas, Maria E, Hu, Mimi I, Jimenez, Camilo

Volltext

Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma von Deschler-Baier, Barbara, Konda, Bhavana, Massarelli, Erminia, Hu, Mimi I, Wirth, Lori J, Xu, Xiaojian, Wright, Jennifer, Clifton-Bligh, Roderick J

Volltext

Denosumab: a new agent in the management of hypercalcemia of malignancy von Thosani, Sonali, Hu, Mimi I

Volltext